Hiv was Gsk’s largest revenue line in fiscal 2025, bringing in $15.37B of $65.33B (24%).
| Products and services [axis] | FY 2015 | FY 2016 | FY 2020 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Shingles, Meningitis, Rsv, Influenza & Established Vaccines | $18.28B | — | |||
| Vaccines | $18.28B | — | |||
| Respiratory | $14.43B | $14.14B | |||
| Established Pharmaceuticals | — | — | |||
| Hiv | $14.18B | $15.37B | |||
| Respiratory, Immunology Inflammation | $6.60B | $7.62B | |||
| Other General Medicines | $6.43B | $5.94B | |||
| Wellness | — | — | |||
| Established Vaccines | $6.68B | $6.24B | |||
| Shingles | $6.73B | $7.12B | |||
| Oral Care | — | — | |||
| Immuno-Inflammation, Respiratory & Other | — | — | |||
| Oncology | $2.82B | $3.95B | |||
| Meningitis | $2.87B | $3.17B | |||
| Nutrition | — | — | |||
| Rsv (Arexvy) | $1.18B | $1.19B | |||
| Skin Health | — | — | |||
| Influenza | $816.00M | $606.00M | |||
| Immuno Inflammation | — | — | |||
| Pandemic | $24.00M | — | |||
| Total | $99.30B | $65.33B |
Gsk brought in $65.33B from its 10 revenue lines in fiscal 2025, the year ended December 31, 2025. Gsk regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $99.30B. Hiv was the largest at $15.37B (23.5%), ahead of Respiratory at $14.14B (21.6%) and Respiratory, Immunology Inflammation at $7.62B (11.7%). The other seven revenue lines brought in $28.20B combined.
Compared with fiscal 2024, Oncology grew fastest, up 40.2% to $3.95B, while Other General Medicines fell the most, down 7.7% to $5.94B.
Gsk stopped reporting Shingles, Meningitis, Rsv, Influenza & Established Vaccines ($18.28B in fiscal 2024), Vaccines ($18.28B in fiscal 2024) and Pandemic ($24.00M in fiscal 2024) as separate revenue lines.
Us was Gsk’s largest region in fiscal 2025, bringing in $33.72B of $48.78B (69%).
| Geography | FY 2015 | FY 2016 | FY 2019 | FY 2020 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Rest Of World | — | — | — | ||||
| Rest Of World. | — | — | — | ||||
| Us | $31.64B | $32.77B | $33.72B | ||||
| International | $15.89B | $16.65B | — | ||||
| Europe | — | $11.92B | $13.70B | ||||
| Uk Current Year Charge | $1.39B | $1.42B | $1.37B | ||||
| Uk | — | — | — | ||||
| Total | $48.91B | $62.75B | $48.78B |
Gsk brought in $48.78B from its three regions in fiscal 2025, the year ended December 31, 2025. That is less than the $65.33B it reports by products and services [axis], so these regions do not cover all of its revenue. Us was the largest at $33.72B (69.1%), ahead of Europe at $13.70B (28.1%) and Uk Current Year Charge at $1.37B (2.8%).
Compared with fiscal 2024, Europe grew fastest, up 15.0% to $13.70B, while Uk Current Year Charge fell the most, down 3.5% to $1.37B. Some of that change comes from Gsk regrouping its regions.
Gsk began breaking out Europe in fiscal 2024, when it brought in $11.92B. Gsk stopped reporting International as a separate region after fiscal 2024, when it brought in $16.65B.
Gsk (GSK) reports its revenue by products and services [axis] and by geography. In fiscal 2025, Hiv was its largest revenue line, bringing in $15.37B (23.5% of the total), followed by Respiratory at $14.14B (21.6%).
Hiv was Gsk's largest revenue line in fiscal 2025, bringing in $15.37B, or 23.5% of the $65.33B total across its 10 revenue lines.
Us was Gsk's largest region in fiscal 2025, bringing in $33.72B, or 69.1% of the $48.78B total across its three regions.
Every figure comes from Gsk's annual financial filings, as reported. Each line keeps the name Gsk gives it, and years follow its fiscal calendar.
Gsk's revenue by products and services [axis] goes back to fiscal 2015, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.